A population-based cohort study of symptomatic gallstone disease in diabetic patients

Table 2 Prevalence of selected comorbidities at baseline in diabetic and control groups, 2000-2008, Taiwan, China

Variables1	Control group		Diabetic group		P value2
	n	%	n	%
Hypertension					< 0.001
No	235 138	38.2	81 913	13.3
Yes	379 733	61.8	533 619	86.7
Gout					< 0.001
No	471 346	76.7	416 400	67.6
Yes	143 525	23.3	199 132	32.4
Hyperlipidemia					< 0.001
No	382 560	62.2	163 598	26.6
Yes	232 311	37.8	451 934	73.4
Cystic fibrosis					0.006
No	614 836	99.9	615 470	99.9
Yes	35	0.1	62	0.1
Cirrhosis					< 0.001
No	589 838	95.9	569 024	92.4
Yes	25 033	4.1	46 508	7.6
Cholangitis					< 0.001
No	605 197	98.4	602 604	97.9
Yes	9674	1.6	12 928	2.1
Caroli’s disease					< 0.001
No	612 979	99.7	613 326	99.6
Yes	1892	0.3	2206	0.4
Crohn’s disease					< 0.001
No	590 912	96.1	590 404	95.9
Yes	23 959	3.9	25 128	4.1
Hemolytic anemia					< 0.001
No	612 100	99.6	612 111	99.4
Yes	2771	0.4	3421	0.6
Total	614 871	100.0	615 532	100.0

¹Hypertension (ICD-9: 401-405, A260, A269), gout (ICD-9: 274), hyperlipidemia (ICD-9: 272.0–272.4, A182), cystic fibrosis (ICD-9: 277.0), cirrhosis (ICD-9: 571.2, 571.5, 571.6), cholangitis (ICD-9: 575.8, 576.1), Caroli’s disease (ICD-9: 576.2), Crohn's disease (ICD-9: 555.0, 555.1, 555.9), hemolytic anemia (ICD-9: 282–283);

²Based on χ² test.